Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | HTT | P42858 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL309863 | 0.86 | LMNA (0.61) | LMNAPTGS1PTGS2MEN1KMT2A | |
| SCHEMBL8008016 | 0.86 | PTGS1 (0.59) | LMNAPTGS1PTGS2MEN1KMT2A | |
| SCHEMBL10174929 | 0.80 | MEN1 (0.43) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL4442685 | 0.80 | S1PR4 (0.41) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL16632695 | 0.80 | L3MBTL1 (0.51) | LMNAPTGS2MEN1KMT2AHTT | |
| SCHEMBL222935 | 0.79 | LMNA (0.56) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL309438 | 0.79 | CYP19A1 (0.62) | LMNAMEN1KMT2AHTTMAPT | |
| SCHEMBL10165092 | 0.78 | TSHR (0.65) | LMNAPTGS1PTGS2MEN1KMT2A | |
| SCHEMBL4824913 | 0.77 | LMNA (0.49) | LMNAPTGS1PTGS2MEN1KMT2A | |
| SCHEMBL4971995 | 0.77 | MEN1 (0.49) | LMNAPTGS1PTGS2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168132-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | MINORYX THERAPEUTICS S.L. (ES) | 2016-06-16 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8093385-B2 | Leukotriene B4 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| CN-101821226-A | Leukotriene b4 inhibitors | HOFFMANN LA ROCHE | 2010-09-01 | — | — | CN | disclosed |
| EP-2190808-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-06-02 | — | — | EP | disclosed |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ALANINE ALEXANDER | 2010-03-25 | — | — | US | disclosed |
| EP-2132184-A1 | NOVEL PYRIMIDINE DERIVATIVES 698 | AstraZeneca AB (SE) | 2009-12-16 | — | — | EP | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-20090054466-A1 | Leukotriene B4 Inhibitors | DOMINIQUE ROMYR | 2009-02-26 | — | — | US | disclosed |
| US-6337351-B1 | AROMATIC OLEFIN AMINES | TARGACEPT, INC. | 2002-01-08 | — | — | US | disclosed |
| WO-2001097786-A2 | BENZOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-12-27 | — | — | WO | disclosed |
| US-6310102-B1 | OXY OR HYDROXY OR NITRO SUBSTITUTED PHENYLALKYLENE AMINE DERIVATIVE USED FOR TREATING A CENTRAL NERVOUS SYSTEM DISORDER CHARACTERIZED BY AN ALTERATION IN NORMAL NEUROTRANSMITTER RELEASE | TARGACEPT, INC. | 2001-10-30 | — | — | US | disclosed |
| US-6262124-B1 | FOR ACTIVATING NICOTINIC CHOLINERGIC RECEPTORS, FOR EXAMPLE, AS AGONISTS OF SPECIFIC NICOTINIC RECEPTOR SUBTYPES; FOR THERAPY OF DYSFUNCTION OF THE CENTRAL AND AUTONOMIC NERVOUS SYSTEMS | TARGACEPT, INC., A CORPORATION OF DELAWARE | 2001-07-17 | — | — | US | disclosed |
| WO-2001017943-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | TARGACEPT, INC. (US) | 2001-03-15 | — | — | WO | disclosed |
| WO-2000078708-A1 | SUBSTITUTED BENZAMIDE INHIBITORS OF RHINOVIRUS 3C PROTEASE | AGOURON PHARMACEUTICALS, INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| US-6166048-A | Pharmaceutical compositions for inhibition of cytokine production and secretion | TARGACEPT, INC. (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000062767-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING PYRIDINE OR PYRIMIDINE DERIVATES FOR INHIBITION OF CYTOKINE PRODUCTION AND SECRETION | TARGACEPT, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
| EP-1042274-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-2000023418-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054466-A1 | Leukotriene B4 Inhibitors | LTB4R2, LTB4R, LTC4S | LMNA 1300/4885PTGS1 31/4885PTGS2 40/4885 |
| US-20100075959-A1 | BENZOTHIAZOLE DERIVATIVES WITH ACTIVITY AS ADENOSINE RECEPTOR LIGANDS | ADORA2A, ADORA1, ADORA3 | LMNA 4033/4885PTGS1 1438/4885PTGS2 1808/4885 |
| US-20160168132-A1 | DI(HETERO)ARYLAMIDES AND SULFONAMIDES, METHODS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | GLB1, GBA1, GALC | LMNA 610/4885PTGS1 1144/4885PTGS2 1584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.